'김갑성'의 전체기사
-
KLN Appointed by Ego Pharmaceuticals as 4PL Partner in Ho…
HONG KONG, Nov. 5, 2025 -- KLN Logistics Group Limited ('KLN'; Stock Code 0636.HK) is pleased to announce the appointment of its pharmaceutical arm, KLN Pharma (Hong Kong) Limited ('KLN Pharma'), as the fourth-party logistics (4PL) service provider for Australian skincare brand Ego Pharmaceuticals in Hong Kong. Under the partnership, KLN Pharma will manage Ego Pharmaceuticals' entire supply chain operations across a wide range of skincare and pharmaceutical products. KLN Pharma will oversee domestic distribution to Ego Pharmaceuticals' retail outlets, pharmacies, drugstores and key cha
- 김갑성
- 2025-11-05 13:42
-
Ultra Maritime Provides Next Generation Torpedo Defence to Au…
ADELAIDE, Australia, Nov. 5, 2025 -- Ultra Maritime, the premier provider of torpedo defence and anti-submarine warfare solutions, has been selected to provide next generation torpedo defence capabilities for the Royal Australian Navy's (RAN) Hunter Class Frigate Program. This award adds to an expanding set of crewed and uncrewed vessels benefiting from Ultra Maritime's pioneering technologies. The Hunter class will deploy Ultra Maritime's Surface Ship Torpedo Defence (SSTD), combining a single in-line towed array with automatic threat alert for unparalleled performance, mainta
- 김갑성
- 2025-11-05 10:48
-
NEC Drives the Future of Smart Living By Elevating Health, Cybers…
BANGKOK, Nov. 5, 2025 -- NEC Corporation (Thailand) Ltd. reaffirms its commitment to creating social value for Thailand by empowering cities, people, and businesses with advanced technology. Guided by NEC's global purpose to "create the social values of safety, security, fairness, and efficiency," the company presents breakthrough innovations aligned with four core pillars — Secure Society from Disaster, Value for Living, Value for Business, and Trust — at the Thailand Smart City Expo 2025, held on 5–7 November at the Queen Sirikit National Convention Center.
- 김갑성
- 2025-11-05 09:19
-
Ascletis Presents Full Analysis of Phase Ib Study of ASC30 Oral…
[ 메디채널 김갑성 기자 ] -Positive data from Phase Ib study of ASC30 oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction; safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs) across all multiple ascending dose (MAD) cohorts. -Phase Ib study data of ASC30 subcutaneous (SQ) injection showed that observed half-life reached 46 days for the treatment formulation (Injection A) and 75 days for the maintenance formulation (Injection B). -Combination of ASC47 and ASC31, a novel peptide agonist targeting both GLP-1R and GIPR, si
- 김갑성
- 2025-11-05 08:10
-
Mölnlycke® establishes first wound care manufacturing site…
CHANGSHU, China and GOTHENBURG, Sweden, Nov. 5, 2025 -- Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, is celebrating the commencement of its new wound care manufacturing site in Changshu, China. This strategic investment marks a milestone in Mölnlycke's growth journey and the beginning of localised manufacturing in one of the world's fastest-growing MedTech markets. "Our site in Changshu marks another step forward in Mölnlycke's ambition to manufacture products closer to where they are sold. It reflects
- 김갑성
- 2025-11-05 08:00
-
Angel Yeast starts Operating New 11,000-Ton Yeast Protein Pro…
YICHANG, China, Nov. 5, 2025 -- Angel Yeast Co., Ltd. (SH600298) has officially started operations at its next-generation yeast protein production line at the Baiyang Biotechnology Park in Yichang, Hubei. The facility has an annual production capacity of 11,000 tons of high-purity yeast protein with a protein content exceeding 80%. This marks a key step in meeting growing global demand for sustainable protein, significantly enhancing the company's global manufacturing footprint and reinforcing its leadership in the alternative protein and sustainable nutrition markets.
- 김갑성
- 2025-11-05 07:52
-
Health In Tech Announces New Davos 2026 Panel: "First Lad…
STUART, Fla., Nov. 5, 2025 -- Health In Tech (Nasdaq: HIT), an Insurtech platform company backed by third-party AI technology, today announced an expansion of its agenda for the Independent InsurTech Summit to be held during World Economic Forum Week 2026 in Davos, Switzerland. Following the previously announced CEO panel, "AI and Institutional Resistance: CEOs Driving Change in Legacy Sectors," Health In Tech will host a second session titled "First Ladies: Backing Women Who Build." The panel will spotlight global leaders advancing women's ent
- 김갑성
- 2025-11-05 07:48
-
INTREPID Alliance Launches Antiviral Toolbox to Support Glob…
Open-access resource includes Registry of Antiviral Compound Libraries to help catalyze drug discovery for priority viruses of pandemic and endemic concern CAMBRIDGE, Mass., Nov. 5, 2025 -- The INTREPID Alliance today announced the launch of the Antiviral Toolbox, an open-access resource to support the global research community in its efforts toward filling the gaps in antiviral R&D that is critical to global health security and the protection of communities worldwide. This curated platform provides easy access to a focused collection of tools and publications, including a
- 김갑성
- 2025-11-05 02:20
-
Metabolon Powers Largest-Ever Veteran Metabolomics Stud…
Metabolon to Support Landmark Million Veteran Program 62,000-sample Dataset Advancing Veteran Health and Multiomics Research MORRISVILLE, N.C., Nov. 4, 2025 -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, today announced that Metabolon's Global Discovery Panel, capable of identifying up to 5,400 annotated biochemicals in a biological sample, was selected to provide biomarker analysis for the Million Veteran Program's (MVP) 62,000
- 김갑성
- 2025-11-04 22:00
-
Grit Biotherapeutics Invited to Deliver Oral Presentation at ASH 20…
BEIJING, Nov. 4, 2025 -- Grit Biotherapeutics Co., Ltd. ("Grit Bio"), a leading clinical-stage biopharmaceutical company pioneering next-generation immunotherapies, today announced that its groundbreaking GT801 in vivo CAR-T program has been selected for an oral presentation at the upcoming 67th American Society of Hematology (ASH) Annual Meeting, to be held December 6–9, 2025, in Orlando, Florida, USA. The abstract, titled "Precision In Vivo CAR-T Generation via CLAMP-Enabled mRNA Delivery: Toward Scalable and Translatable Cell Therapy," was a
- 김갑성
- 2025-11-04 21:15
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-11_THU
- ADI Foundation、ADI ChainのメインネットとADIユーティリティトークンのローンチを発表 02:48
- ADI 재단, ADI 체인 메인넷 및 ADI 유틸리티 토큰 출시 02:31
- ADFW's Fintech Abu Dhabi Points to a New Era of Finance Fuelled by Innovation and Disruption 02:02
- カタール博物館のTasweer 、「文化の年（Years of Culture）」の一環として「一つの空の下（Under One Sky）」世界写真公募を発表 00:54
- 카타르 박물관 타스위르, '같은 하늘 아래' 국제 사진 공모전 개최 00:29
2025-12-10_WED
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 11일 04시 20분